Hemo AI

Company Overview

Snapshot

Founded in October 2023 by Liron Ben-Bashat Bergman, David Salton, Ron Beloosesky, and Gilad Cohen, Hemo AI operates with 1–10 employees. The company is currently in the Pre-Funding stage, focusing on developing an AI-powered IV blood monitoring medical device.

Business overview

Hemo AI is a Health Tech & Life Sciences company developing an AI-powered IV blood monitoring medical device. Its core technology provides an automated, wearable system that integrates data aggregation and AI analysis to deliver real-time alerts for bleeding and sepsis. The company's solution is designed for use in various medical environments, including hospitals, ICUs, ambulances, and field hospitals, serving the healthcare, defense, and government sectors.

Company Intelligence Q&A

What is Hemo AI's primary focus?

Hemo AI is focused on developing an AI-powered IV blood monitoring medical device designed to provide real-time alerts for bleeding and sepsis, thereby enhancing patient care.

When was Hemo AI founded?

Hemo AI was founded in October 2023.

Who are the founders of Hemo AI?

Hemo AI was founded by Liron Ben-Bashat Bergman, David Salton, Ron Beloosesky, and Gilad Cohen.

What markets does Hemo AI target?

Hemo AI targets the healthcare, defense, and government sectors, with its technology applicable in hospitals, ICUs, ambulances, and field hospitals.

What is the current product stage of Hemo AI?

Hemo AI's product is currently in the R&D stage, as of May 2025.